FDA Grants Fast Track Status to Peanut Allergy Immunotherapy PVX108

The FDA has granted Fast Track designation to PVX108, a novel peptide immunotherapy targeting peanut allergy, aimed at enabling faster development and potential earlier patient access. A phase 2 pediatric trial is ongoing with interim results expected in late 2026.

This Wire brief sits within Fusion42's coverage of Biotech.